Global Roundup: Ginkgo/Microba Autoimmune Pact and New Parkinsons Data
Summary
"We believe the human microbiome currently represents a missing piece in the treatment of major chronic diseases, and as a result a number of microbiome-based therapeutics are progressing through clinical development globally" Luke Reid, chief executive officer of Microba said in a statement. "Ginkgos high throughput screening automation combined with our novel data-driven approach to therapeutic discovery from the microbiome can potentially accelerate development of breakthrough new drugs for autoimmune diseases." The data suggest that P2B001 can significantly improve motor symptoms and daily function without triggering side effects such as daytime sleepiness, orthostatic hypotension and hallucinations associated with higher doses of dopamine agonists. The increased capacity available will allow eTheRNAs research departments to enhance their investigations on a variety of mRNA and lipid nanoparticles for R&D applications, which are expected to result in improved control and faster production cycles. The companies will aim to develop and commercialize a gene therapy product based on ViGenerons novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).